BLISSGVS (BLISSGVS): Promoter Buying
Bliss GVS Pharma Limited has filed an addendum to its public announcement and detailed public statement regarding an open offer by Anupam Rasayan Limited, the acquirer, for the addition of a person acting in concert (PAC), according to an NSE filing dated 19 July 2026. The disclosure, made at 20:47, relates to promoter-side activity in the context of the ongoing open offer process.
Events classified as promoter buying have historically shown a 65.2% win rate across 23 comparable instances in Strota's database, with a net edge of 1.222%. This base rate reflects how similar announcements have performed in the past, not a forecast for this specific stock.
The company trades at a price-to-earnings ratio of 40.33 and a price-to-book ratio of 4.29, with a market capitalisation of ₹5,137 crore. Return on equity stands at 11.6%, while the dividend yield is 0.41%. On 29 June 2026, MATEUS LTD bought shares worth ₹56.35 crore in a bulk deal, with ARIAN INVESTMENT LTD selling an identical amount the same day. The stock has also seen multiple director and key managerial personnel resignations in early July 2026, including the departure of Chief Executive Officer Narsimha Shibroor Kamath effective 14 July 2026.
The filing establishes the procedural update to the open offer but does not specify terms, pricing, or completion timelines. The historical base rate for promoter buying events and the recent institutional cross-trade are observable data points; they do not establish causality or predict price movement.
The catalyst
Bliss GVS Pharma Limited has informed the Exchange about Addendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC. (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Promoter Buying tends to continue — the move went bullish in about 65.2% of next sessions (net 1.222% after drift and cost, n=23). A base rate, not a forecast for this stock.
BLISSGVS right now
P/E 40.33. Full BLISSGVS analysis →
Sources
- Bliss GVS Pharma Limited has informed the Exchange about Addendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC. — NSE
- Is It Smart To Buy Bliss GVS Pharma Limited (NSE:BLISSGVS) Before It Goes Ex-Dividend? — simplywall.st
- Should You Be Adding Bliss GVS Pharma (NSE:BLISSGVS) To Your Watchlist Today? — simplywall.st
- Bliss GVS Pharma Board Meeting Scheduled on May 12, 2026 to Approve Q4 FY26 Results and Final Dividend — scanx.trade
- Bliss GVS Pharma's (NSE:BLISSGVS) 37% CAGR outpaced the company's earnings growth over the same three-year period — webull.com.my
Keep digging
- BLISSGVS — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.